- Home
- DBRG vs IMCR Comparison
DBRG vs IMCR Comparison
Compare DBRG & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- IMCR
- Stock Information
- Founded
- DBRG 1991
- IMCR 2008
- Country
- DBRG United States
- IMCR United Kingdom
- Employees
- DBRG N/A
- IMCR N/A
- Industry
- DBRG Real Estate Investment Trusts
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DBRG Real Estate
- IMCR Health Care
- Exchange
- DBRG Nasdaq
- IMCR Nasdaq
- Market Cap
- DBRG 1.8B
- IMCR 1.8B
- IPO Year
- DBRG 2009
- IMCR 2021
- Fundamental
- Price
- DBRG $10.40
- IMCR $32.99
- Analyst Decision
- DBRG Strong Buy
- IMCR Buy
- Analyst Count
- DBRG 8
- IMCR 10
- Target Price
- DBRG $15.81
- IMCR $58.13
- AVG Volume (30 Days)
- DBRG 1.8M
- IMCR 265.5K
- Earning Date
- DBRG 08-07-2025
- IMCR 08-11-2025
- Dividend Yield
- DBRG 0.38%
- IMCR N/A
- EPS Growth
- DBRG N/A
- IMCR N/A
- EPS
- DBRG 0.32
- IMCR N/A
- Revenue
- DBRG $566,324,000.00
- IMCR $333,581,000.00
- Revenue This Year
- DBRG N/A
- IMCR $26.82
- Revenue Next Year
- DBRG $27.31
- IMCR $8.15
- P/E Ratio
- DBRG $27.86
- IMCR N/A
- Revenue Growth
- DBRG N/A
- IMCR 25.75
- 52 Week Low
- DBRG $6.41
- IMCR $23.15
- 52 Week High
- DBRG $17.33
- IMCR $40.15
- Technical
- Relative Strength Index (RSI)
- DBRG 41.04
- IMCR 41.17
- Support Level
- DBRG $10.69
- IMCR $32.00
- Resistance Level
- DBRG $11.13
- IMCR $36.20
- Average True Range (ATR)
- DBRG 0.33
- IMCR 1.45
- MACD
- DBRG -0.05
- IMCR -0.41
- Stochastic Oscillator
- DBRG 4.74
- IMCR 17.60
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.